ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.

Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter ...

AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, ...

AngioDynamics prepares to report fiscal fourth-quarter results as attention turns to revenue trends, device demand, valuation, and business progress.

Q4 sales grew 13% year over year, although gross profit margins on those sales declined by 160 basis points, to 52.7%. Adjusted earnings still ended up better than expected, and AngioDynamics cut its ...

AngioDynamics’ DIRECT clinical study features a comprehensive data collection strategy that will provide meaningful clinical information to healthcare professionals, support a regulatory indication ...

CEO Jim Clemmer declared: "We had an outstanding first quarter as we continued to build off of the strong momentum created in fiscal 2025." But not all of AngioDynamics's news was good. Sales grew 12% ...

Recently, AngioDynamics (ANGO) inked a definitive agreement to acquire the outstanding capital stock of privately-owned Vortex Medical Inc. for $15 million in cash. The acquisition is expected to ...

The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business ...